ReviewOral oncology2014
Is radiation dose reduction the right answer for HPV-positive head and neck cancer?
Review in Oral oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- CARWL score as a predictor of radiation-induced periodontitis in locally advanced head and neck cancer undergoing concurrent chemoradiotherapy.Biomolecules & biomedicine · 2025Article
- Liquid Biopsies for Molecular Biology-Based Radiotherapy.International journal of molecular sciences · 2021Review
- Pulsed low dose-rate irradiation response in isogenic HNSCC cell lines with different radiosensitivity.Radiology and oncology · 2020Article
- Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma.International journal of biological sciences · 2020Review
- Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.Radiation oncology (London, England) · 2019Article
- Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2019Article
- The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment.International journal of radiation oncology, biology, physics · 2017Review
- Article
- Human papillomavirus and head and neck carcinomas: focus on evidence in the babel of published data.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2016Review
- Article
- HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies.Cancers · 2016Review
- Modulation of therapeutic sensitivity by human papillomavirus.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2015Review
- The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.Annals of translational medicine · 2015Article
- Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck.Journal of sexually transmitted diseases · 2015Review
- Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.Cell death & disease · 2014Article
- Clinical and scientific impact of human papillomavirus on head and neck cancer.World journal of clinical oncology · 2014Review
- Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time.Chemical research in toxicology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with head and neck squamous cell carcinoma (HNC) related to human papillomavirus (HPV) represent a growing and distinct patient cohort with unique molecular and epidemiologic characteristics. These patients have markedly improved survival outcomes compared to those with traditional HNC, leading some to advocate for treatment dose reduction. In this article, we review ongoing clinical trials investigating several ways to reduce therapeutic intensity for patients with HPV-positive HNC, discuss the risks and benefits associated with these trials, and summarize the data underlying the advancement of dose reduction trials for patients with HPV-positive HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.